Kentucky is first in the nation in overall cancer mortality rate. Here at Markey, our five-year goal is to decrease Kentucky’s cancer deaths by 50%. Toward that goal, Markey is treating over 3,000 new cancer cases each year. And each patient we treat is a celebration of survivorship.
Survivorship, during or after treatment, is a badge of honor. It can also be a heavy burden adjusting to physical and emotional changes that come with treatments, side effects and others changes in life after a diagnosis. Markey’s comprehensive care includes an intense focus on the issues of survivorship.
Read more »
Read more »
Read more »
Read more »
Read more »
Read more »
LEXINGTON, Ky. (Nov. 24, 2015) – The University of Kentucky Markey Cancer Foundation is pleased to announce the hiring of Michael Delzotti, CFRE, CSPG, as new president and chief executive officer. Delzotti will begin his new role in early December.
The UK Markey Cancer Foundation serves as the fundraising arm for the UK Markey Cancer Center, the only National Cancer Institute-designated cancer center serving Kentucky and the surrounding Appalachian area. The Foundation underwent a nationwide search for their new president and chief executive officer this past summer.
Delzotti comes to Markey from the world-renowned and number one-ranked University of Texas MD Anderson Cancer Center in Houston, where he served as senior director of philanthropic resources. There his role focused on two successive $1.25 billion campaigns. He also directed a $60 million campaign focused on discovering novel drug therapies for Alzheimer’s disease.
Prior to Delzotti’s tenure with MD Anderson Cancer Center, he held major leadership positions with Rice University, UCLA and the Special Olympics of Southern California.
“I am honored to have been chosen by the UK Markey Cancer Foundation Board to join them in their effots,” said Delzotti. “This Center has such a distinguished history of providing world-class care for the citizens of Kentucky and producing cutting-edge research for the entire field of cancer care.
“Our number one goal will be to build the relationships necessary to support Dr. (Mark) Evers’s vision of elevating Markey to NCI Comprehensive Cancer Center status. This designation is so important because it means additional advanced research and comprehensive care for our patients and their families. The Center and the Foundation have one focus – to care for the patient and cure this disease.”
In his new role with the UK Markey Cancer Foundation, Delzotti will also serve as the Foundation’s chief development officer, focusing on major gift development and corporate and foundation grants, as well as overseeing capital campaign initiatives and all other aspects of the Foundation.
"With government funding for cancer research waning, philanthropy is critical to the continued success of NCI-designated cancer centers," said Dr. Mark Evers, director of the UK Markey Cancer Center. "I look forward to working with Mike to help support and grow so many of the outstanding clinical and research programs we have here at Markey."
With Kentucky’s status as the nation’s leader for overall cancer incidence and mortality, the UK Markey Cancer Center plays an important role in supporting patients around the Commonwealth. Since achieving NCI-designated status in 2013, the Markey Cancer Center has undertaken several new initiatives in the areas of research, treatment and prevention.
“From the moment the search committee sat down with Mike for the first time, we knew he had so much to offer, said UK Markey Cancer Foundation Board Chair Sally Humphrey. “Mike’s experience at MD Anderson, one of the world’s most respected cancer centers, and his thorough knowledge of healthcare fundraising will allow him to best equip the Foundation to secure financial support for groundbreaking research and ultimately help Dr. Evers and his team to achieve NCI Comprehensive Cancer Center status.”
Media Contact: Kristi Lopez, email@example.com
LEXINGTON, Ky. (Oct. 20, 2015) – Time for Three, a string trio known for defying tradition and reinventing classical music in the contemporary world, will perform four pop-up concerts at UK HealthCare locations and in the Lexington community this week.
Known for their virtuosity and showmanship, Time for Three takes an innovative approach to classical composition by incorporating a variety of musical styles, including country western, Bluegrass and jazz, in their high-energy performances. Violinist Zach DePue, violinist Nick Kendall and double-bassist Ranaan Meyer share a passion for improvisation, composition and arrangement, which are prime elements of their musical ensemble. The classically trained musicians blend Bach with the Beatles, specializing in original mash-ups with hits from artists including Katy Perry, Kanye West and more.
The group went viral on YouTube and debuted as a top-10 album on Billboard’s Classical Crossover chart. In addition to appearances on the BBC and ABC’s Dancing with the Stars, the group has performed with the Melbourne Symphony Orchestra and at Carnegie Hall. Individual soloists have performed with the Philadelphia Orchestra and completed prestigious residences at the Kennedy Center.
Pop-up concerts will be held:
· October 21 at Noon, UK Chandler Hospital Pavilion A Atrium
· Oct. 21 at 2:30 p.m., Eastern State Hospital
· October 22 at 10 a.m., Discovery Education Concert at Keeneland and Keeneland National Anthem
· Oct. 22 at 7 p.m., Ethereal Brewery
The pop-up concerts build momentum to the group’s Oct. 23 performance and presentation at the Singletary Center for the Arts as part of the UK HealthCare Saykaly Garbulinska Performer in Residence Series. The UK Arts in HealthCare program in partnership with the Lexington Philharmonic and the UK School of Music will present Time for Three Music Entrepreneurship Assembly at 1 p.m. This event is free and open to the public.
The UK School of Music at UK College of Fine Arts has garnered national reputation for high-caliber education in opera, choral and instrumental music performance, as well as music education, composition and music theory.
The UK Arts in HealthCare program's mission is to harness the healing power of art to create a comfortable environment focused on the spiritual and emotional well-being of patients, visitors and employees.
The mission of the Lexington Philharmonic is to foster excellence and innovation in the performance and presentation of great music; to enrich the lives of our diverse citizenry; to educate current and future audience and to bring distinction to our community through the orchestra’s presence and standing.
MEDIA CONTACT: Elizabeth Adams, firstname.lastname@example.org
LEXINGTON, Ky. (Oct. 7, 2015) – UK HealthCare has more than 125 physicians practicing medicine with UK Albert B. Chandler Hospital, Kentucky Children's Hospital, UK Good Samaritan Hospital and Shriner's Hospitals for Children who appear on the Best Doctors in America list for 2015-16 – more than any other hospital in Kentucky. Only 5 percent of doctors in America earn this honor, decided by impartial peer review.
The Best Doctors in America list, assembled by Best Doctors Inc. and audited and certified by Gallup, results from polling of more than 40,000 physicians in the United States. Doctors in more than 40 specialties and 400 subspecialties of medicine appear on this year’s List.
The experts who are part of the Best Doctors in America database provide the most advanced medical expertise and knowledge to patients with serious conditions – often saving lives in the process by finding the right diagnosis and right treatment.
2015-16 Best Doctor's List:
Sadiq Ahmed Nephrology
Kenneth B. Ain Endocrinology and Metabolism
Michael I. Anstead Pediatric Specialist
Rony K. Aouad Otolaryngology
Susanne M. Arnold Medical Oncology and Hematology
Henrietta Salvilla Bada Pediatric Specialist
Hubert O. Ballard Pediatric Specialist
Robert J. Baumann Child Neurologist
Louis Bezold Pediatric Specialist
Peter James Blackburn Ophthalmology
Christopher A. Boarman Pediatrics
David C. Booth Cardiovascular Disease
Edwin A. Bowe Anesthesiology
Robert A. Broughton Pediatric Specialist
Raeford E. Brown, Jr. Pediatric Specialist
Scottie B. Day Pediatric Specialist
Christopher P. DeSimone Obstetrics and Gynecology
Philip A. DeSimone Medical Oncology and Hematology
David J. DiSantis Radiology
John Draus Pediatric Specialist
John H. Eichhorn Anesthesiology
Eric D. Endean Vascular Surgery
Deborah R. Erickson Urology
B. Mark Evers Surgery
John L. Fowlkes Pediatric Specialist
Peter J. Giannone, Jr. Pediatric Specialist
Jacqueline S. Gibson Internal Medicine
Larry B. Goldstein Neurology
Donna G. Grigsby Pediatrics
John C. Gurley Cardiovascular Disease
Wendy Fetterman Hansen Obstetrics and Gynecology
Andrew Hoellein Internal Medicine
Robert Hosey Family Medicine
Joseph A. Iocono Pediatric Specialist
Mary Lloyd Ireland Orthopaedic Surgery
Henry Iwinski Pediatric Specialist
Gregory A. Jicha Neurology
Darren Lee Johnson Orthopaedic Surgery
Raleigh O. Jones Otolaryngology
Jamshed F. Kanga Pediatric Specialist
Dennis Karounos Endocrinology and Metabolism
Edward J. Kasarskis Neurology
Douglas G. Katz Ophthalmology
Philip A. Kern Endocrinology and Metabolism
Stefan G. Kiessling Pediatric Specialist
Mahesh R. Kudrimoti Radiation Oncology
Cheri D. Landers Pediatric Specialist
Philip B. Latham Pediatrics
Steve W. Leung Cardiovascular Disease
Robert W. Lightfoot, Jr. Rheumatology
Richard Lock Anesthesiology
Grace F. Maguire Pediatrics
Scott D. Mair Orthopaedic Surgery
Hartmut H. Malluche Nephrology
Jeremiah T. Martin Thoracic Surgery
Erich C. Maul Pediatrics
Hanna W. Mawad Nephrology
Ronald Charles McGarry Radiation Oncology
Patrick C. McGrath Surgical Oncology
Adrian W. Messerli Cardiovascular Disease
Todd Milbrandt Pediatric Specialist
David J. Minion Vascular Surgery
Amr El-Husseini Mohamed Nephrology
David J. Moliterno Cardiovascular Disease
Alba E. Morales Pediatric Specialist
Peter E. Morris Critical Care Medicine
Timothy W. Mullett Thoracic Surgery
Kevin R. Nelson Neurology
Nicholas J. Nickl III Gastroenterology
M. Elizabeth Oates Radiology
John M. O'Brien, Jr. Obstetrics and Gynecology
Hatim A. Omar Pediatric Specialist
Amit Patel Plastic Surgery
Kevin A. Pearce Geriatric Medicine
P. Andrew Pearson Ophthalmology
Luther C. Pettigrew, Jr. Neurology
Barbara A. Phillips Sleep Medicine
Thomas Pittman Pediatric Specialist
Andrew R. Pulito* Pediatric Specialist
Marcus E. Randall Radiation Oncology
Annette Rebel Critical Care Medicine
Hassan K. Reda Thoracic Surgery
Aru Reddy Pediatric Specialist
L. Raymond Reynolds Endocrinology and Metabolism
Julie Ribes Pathology
Scott A. Riley Hand Surgery
John J. Rinehart* Medical Oncology and Hematology
Kimberly Ringley Pediatrics
William C. Robertson, Jr. Child Neurologist
David W. Rudy Clinical Pharmacology, Internal Medicine
Sarah S. Rugg Cardiovascular Disease
Sibu P. Saha Thoracic Surgery
Sheila P. Sanders Ophthalmology
B. Peter Sawaya Nephrology
Douglas J. Schneider Pediatric Specialist
Jeffrey Bryan Selby Orthopaedic Surgery
Lori Shook Pediatric Specialist
Michael Sekela Thoracic Surgery
John Slevin Neurology
David A. Sloan Surgical Oncology
Charles D. Smith, Jr. Neurology
Mikel D. Smith Cardiovascular Disease
Susan Smyth Cardiovascular Disease
Vincent L. Sorrell Cardiovascular Disease
William Henry St. Clair Radiation Oncology
Carol Steltenkamp Pediatrics
Julia C. Stevens Pediatric Specialist
Stephen Strup Urology
Lisa R. Tannock Endocrinology and Metabolism
Vishwas R. Talwalkar Pediatric Specialist
Alice C. Thornton Infectious Disease
Kathryn M. Thrailkill Pediatric Specialist
Phillip A. Tibbs Neurological Surgery
Dale E. Toney Internal Medicine
Fred Rand Ueland Obstetrics and Gynecology
Joseph Valentino Otolaryngology
Craig Van Horne Neurological Surgery
Woodford S. Van Meter Ophthalmology
John R. van Nagell Obstetrics and Gynecology
Henry C. Vasconez Pediatric Specialist, Plastic Surgery
Lars M. Wagner Pediatric Specialist
Carmel Wallace Pediatrics
Gretchen Lois Wells Cardiovascular Disease
Thomas French Whayne, Jr. Cardiovascular Disease
Michael L. Wittkamp Pediatric Specialist
Thomas L. Young Pediatrics
Khaled M. Ziada Cardiovascular Disease
Joseph B. Zwischenberger Critical Care Medicine, Thoracic Surgery
LEXINGTON, Ky. (Sept. 14, 2015) — A University of Kentucky study shows that withaferin A, a component of Withania somnifera (winter cherry) plant extract, may hold promise as a new treatment for non-Hodgkin’s lymphoma.
Winter cherry extract was used in traditional Ayurvedic Indian medicine for thousands of years before it caught the interest of Subbarao Bondada, a University of Kentucky College of Medicine professor and researcher for the UK Markey Cancer Center. Because withaferin A shows promise in treating other cancers without the side effects associated with current treatments, Bondada’s laboratory tested it against lymphoma. Non-Hodgkin’s lymphoma is one of the most common cancers in the U.S. and is known for being particularly aggressive.
Unlike other studies using withaferin A to treat cancer, Bondada’s study, published in the journal Cancer Biology and Therapy, is the first to test the chemical against a blood cancer. Previous studies using withaferin A focused on cancers producing tumors that grow as a mass in tissue, more commonly known as solid tumors.
Katie McKenna, a graduate student in Bondada’s laboratory, found that withaferin A prevented the lymphoma cells from dividing and ultimately killed them. Specifically, they found withaferin A directly targeted a signaling pathway in the cancer it needs to survive.
“It may be possible to develop orally administered versions of withaferin A that could be used in lymphoma patients with fewer side effects than current chemotherapy regimens,” Bondada said.
Because withaferin A shows promise in treating non-Hodgkin lymphoma, Bondada’s team is now testing the chemical on chronic lymphocytic leukemia cells.
Bondada's group collaborated with University of Louisville Professor Ramesh Gupta, who aided in the isolation of withaferin A. This work was funded by the National Cancer Institute to the UK Markey Cancer Center, the National Institutes of Health, Office of Vice President for Research for Core Research facilities and the Sabinsa Corporation and does not necessarily represent the views of these institutions.
MEDIA CONTACT: Allison Perry, 859-323-2399 or email@example.com
LEXINGTON, Ky. (Sept. 2, 2015) – This Saturday, the University of Kentucky Markey Cancer Center is hosting its second annual "Tealgate" event before the UK vs. University of Louisiana at Lafayette football game.
The event was created to raise ovarian cancer awareness. UK offers an UK Ovarian Cancer Screening Program, a free program that offers ultrasound screenings to Kentucky women over the age of 50 and women over the age of 25 who have had a family history of ovarian cancer.
Tealgate is free and open to the public. Participants are encouraged to wear teal, the color that represents ovarian cancer. Parking is free beginning at 5 p.m., but participants must request a parking pass in advance by contacting firstname.lastname@example.org.
MEDIA CONTACT: Allison Perry, email@example.com or (859) 323-2399
LEXINGTON, Ky. (Sept. 8, 2015) -- An investigational medical device for the treatment of late stage lung cancer, pioneered by researchers at University of Kentucky, has been approved for clinical trials by the Food and Drug Administration (FDA). UK is the only site in the country approved to test this new treatment on advanced lung cancer patients.
The Exatherm Total Body Hyperthermia System (Exatherm-TBH) was developed at UK in a public-private partnership with Exatherm Inc. The project is supported by grant funding from the National Institutes of Health.
The research team includes Dr. Jeremiah Martin, surgical director of the UK Markey Cancer Center’s Multidisciplinary Lung Cancer Clinic; and Dr. Kevin Hatton, chief of anesthesiology critical care at UK.
“Cancer cells are more susceptible to damage from heat than normal tissue, so the development of a safe method to deliver heat throughout the body may be a key step forward for advanced lung cancer patients,” said Martin.
Whereas most thermal treatments are specific to the area of the body where a tumor is located, UK researchers are examining total body hyperthermia, a treatment utilizing a perfusion circuit that circulates the blood through the patient’s vascular system at a target temperature.
“Patients with advanced lung cancer, who have completed standard therapy and for whom there are no additional conventional options, are invited to learn more about this trial,” Martin said. “This initial safety trial will lay important groundwork for patients with other tumor types in the future.”
The goal in any cancer treatment is to attack the diseased cells and leave the healthy cells alone. Healthy cells have a signaling mechanism that protects them from increases in body temperature. This mechanism is defective in cancer cells, which the potential new treatment aims to exploit.
The treatment, which lasts approximately four hours under a general anesthetic, uses the Exatherm-TBH System to heat and circulate the blood throughout the body. The device heats the patient’s blood to a temperature of 42 degrees Celsius, or about 107 degrees Fahrenheit.
Because systemic hyperthermia attacks cancer cells throughout the body all at once, the research team hopes the project will lead to a new and safe method for treating patients whose cancer has metastasized through the body.
"If results meet our expectations, the approach would present an advantage over other methods of thermal treatment, particularly in later stages of the disease," said Martin.
Patients who want to find out if they are eligible to participate in this study may visit UKClinicalResearch.com or call the division of UK Cardiothoracic Surgery at 859-323-6494.
Physicians: to refer a patient, contact Dr. Jeremiah Martin through the UK physician referral service toll free at 800-888-5533 or 859-231-9922.
To learn more about participating in research, including current opportunities at UK and across the country, visit http://www.ccts.uky.edu/ccts/participate-research.
MEDIA CONTACT: Allison Perry, firstname.lastname@example.org; or Mallory Powell, email@example.com
GLASGOW, Ky. (Aug. 27, 2015) – T.J. Samson Community Hospital in Glasgow, Ky., announced that it has entered into a formal collaboration with the University of Kentucky Markey Cancer Center to further develop its oncology service line.
“At T.J. Samson we have wonderful medical professionals that are excellent at providing individualized treatment options. By collaborating with the Markey Cancer Center, we have just provided them a whole new world of resources to offer their patients locally,” Bud Wethington, CEO/President of T.J. Regional Health.
Kentucky faces some of the highest rates of cancer incidence and mortality in the nation. By working with Markey, T.J. Samson is committed to providing top-notch care for its cancer patients. The hospital is considered a candidate member of the UK Markey Cancer Center Affiliate Network (MCCAN) and is making steps toward becoming a full affiliate member.
As part of the formal collaboration, the UK Markey Cancer Center will assist T.J. Samson in preparing for their American College of Surgeons' Commission on Cancer accreditation, which is the quality standard for all MCCAN sites.
"We are excited to work with T.J. Samson in building a strong oncology program," said Dr. Timothy Mullett, medical director of the MCCAN. "Our state unfortunately ranks at the top in terms of cancer incidence and mortality, but by working together with hospitals across the state, we have the potential to make a serious impact on cancer prevention and care."
T.J. Samson currently provides oncology services at the T.J. Health Pavilion under the direction of Dr. Donald Goodin. Goodin is board-certified in hematology/oncology and works closely with Dr. William Tyree at the Barren River Regional Cancer Center, a joint venture between T.J. Samson Community Hospital and The Medical Center of Bowling Green. Tyree is board-certified in radiation oncology and has been practicing in southcentral Kentucky since 2013.
These physicians, along with their highly trained staff, provide complex oncology services including diagnostic imaging, surgery, radiation, palliative care and chemotherapy close to home. The new relationship with Markey will strengthen patient navigation, psychosocial support, survivorship and rehabilitation services.
“I look forward to being able to expand the scope of services at T.J. Samson Community Hospital,” Goodin said. “Our specialized physicians desire to provide opportunities for their patients to participate in clinical trials through a collaborative affiliation with a nationally recognized program such as the University of Kentucky Markey Cancer Center.”
The Markey Cancer Center was founded in 1983 and is a dedicated matrix cancer center established as an integral part of the University of Kentucky and the UK HealthCare enterprise. Markey functions as a multi-faceted, multidisciplinary complex whose mission is to reduce cancer morbidity and mortality through a comprehensive program of cancer education, research, treatment and community engagement.
In July 2013, Markey was designated by the National Cancer Institute (NCI) to receive research funding and many other opportunities available only to the nation’s best cancer centers. Markey is the only NCI-designated center in Kentucky and one of only 69 in the country.
The clinical programs and services of the Markey Cancer Center are integrated with the UK Albert B. Chandler Hospital. Markey's cancer specialty teams work together with UK Chandler Hospital departments and divisions to provide primary patient care and support services as well as advanced specialty care with applicable clinical research studies. All diagnostic services, clinical and pathology laboratories, operating rooms, emergent and intensive care, and radiation therapy services are also provided to cancer patients through UK Chandler Hospital. Attending Physicians affiliated with the Center are board certified in their respective oncologic specialties, and its research scientists are generously funded by nationally prominent funding agencies, including the National Cancer Institute.
MEDIA CONTACT: Allison Perry, (859) 323-2399 or firstname.lastname@example.org
LEXINGTON, Ky. (Aug. 13, 2015) – The National Cancer Institute (NCI) recently awarded a $750,000 grant to University of Kentucky researcher Fredrick Onono to study the potential link between obesity and breast cancer.
Obese women are four times more likely to develop treatment-resistant breast cancer, but the exact mechanism for this observation is still largely a mystery. The link between high-fat diets and cancer development provides a clue that fats themselves may somehow be responsible for causing cells to malfunction.
Onono, who recently became an assistant professor at the University of Kentucky, will work with fellow UK researchers Andrew Morris, Ashwini Anand Professor of Cardiology; Dr. Susan Smyth, Jeff Gill Professor of Cardiology; Kathleen O’Connor, professor of molecular and cellular biochemistry; and Andrew Lane, professor of toxicology and cancer biology.
This research is made possible by an award from the National Cancer Institute of the National Institutes of Health under award number 1K01CA197073-01 and does not necessarily represent the official views of the National Institutes of Health.
Video Produced by UK Public Relations & Marketing. To view captions for this video, push play and click on the CC icon in the bottom right hand corner of the screen. If using a mobile device, click on the "thought bubble" in the same area.
LEXINGTON, Ky. (Aug. 10, 2015) – The University of Kentucky's Dr. John D'Orazio recently received grant funding totalling $375,000 over three years to further his research on melanoma, the deadliest form of skin cancer.
Three organizations provided an equal share of the funding: the Melanoma Research Alliance (MRA), the largest private funder of melanoma research; the Markey Cancer Foundation; and DanceBlue, the University of Kentucky's student-run fundraiser for pediatric cancer. Additionally, much of the preliminary data used in the MRA grant application was facilitated by pilot funding from the University of Kentucky’s Center for Clinical and Translational Sciences.
D'Orazio's research focuses on the hormonal pathways that protect the skin from sun damage and how efficiently the skin's DNA may be able to repair itself. In a previous study, D'Orazio's team discovered a genetic defect in the melanocortin1 receptor (MC1R) leads to a reduced ability to repair DNA, making people more susceptible to developing melanoma.
The new project will focus on the specific hormones that appear to "turn off" MC1R signaling, also leading to an increased likelihood of developing the cancer.
Melanoma of the skin is one of the most common cancers in the United States and among the top 10 causes of new cancer cases. In the United States each year, more than 76,000 Americans are diagnosed with melanoma, and it is one of the most common cancers for young women. While the overall five-year survival rate for people diagnosed with melanoma is high at 92 percent, the survival rate decreases dramatically once melanoma spreads to other parts of the body.
LEXINGTON, Ky. (Aug. 6, 2015) – Jennifer Bradley, the Jin Shin Jyutsu practitioner at the University of Kentucky Markey Cancer Center, has been nominated for a Buffalo Trace Distillery Eagle Rare Life Honor for her hard work and devotion to Markey's Jin Shin Jyutsu program.
Buffalo Trace Distillery recognizes and honors those who share a passion for excellence with their Rare Life Award. The nominee in each of five categories who receives the most public votes will win $5,000 for the charity of their choice and the top overall winner receives $50,000.
Bradley became interested in Jin Shin Jyutsy after seeing how the practice helped two of her own family members who had been diagnosed with cancer. Jin Shin Jyutsu is an ancient form of touch therapy similar to acupuncture in philosophy. Studies have shown that it can help to reduce the physical and emotional effects of cancer diagnosis and treatment. Jin Shin Jyutsu has been offered at the Markey Cancer Center since 2009.
Voting for the award is open through December and you may vote up to once each day.
MEDIA CONTACT: Allison Perry, (859) 323-2399 or email@example.com
LEXINGTON, Ky. (July 7, 2015) – A new study led by University of Kentucky researchers suggests a new approach to develop highly-potent drugs which could overcome current shortcomings of low drug efficacy and multi-drug resistance in the treatment of cancer as well as viral and bacterial infections.
Published in Nanomedicine, the study identified a new mechanism of targeting multi-subunit complexes that are critical to the function of viruses, bacteria or cancer, thus reducing or possibly even eliminating their resistance to targeted drugs.
The study was led by Peixuan Guo, director of UK's Nanobiotechnology Center and one of the top nanobiotechnology experts in the world. Guo holds a joint appointment at the UK Markey Cancer Center and in the UK College of Pharmacy.
"Efficacy is the key in drug development,” Guo said. "Inhibiting multisubunit targets works similar to the series-circuit Christmas decorating light chains; one broken bulb turns off the entire lighting system."
By targeting RNA or protein subunits that have multiple sites for inactivation, but that are inextricably linked, this method allows for killing or disabling the RNA or protein without requiring the inhibition of multiple pathways that might be used by the organism to remain active and viable (and thus, multiple drugs are not needed, as well). Using this method, a single subunit targeting to the target RNA or protein subunits that is unique and assenting for the organism, the organism will be disabled or die and thus, no longer able to cause disease.
“One of the vexing problems in the development of drugs is drug resistance,” said Tim Tracy, former Dean of the UK College of Pharmacy and current UK provost. “Dr. Guo's study has identified a new mechanism of efficiently inhibiting biological processes that are critical to the function of the disease-causing organism, such that resistance is minimized or eliminated.”
Guo focuses much of his work on the use of ribonucleic acid (RNA) nanoparticles and a viral nano-motor to fight cancer, viral infections and genetic diseases. He is well-known for his pioneering work of constructing RNA nanoparticles as drug carriers. Guo's research team also includes Dan Shu, Farzin Haque, Mario Vieweger, Fengmei Pi, Hui Zhang, Yi Shu, Chi Wang, Peng Zhang, Ashwani Sharma, Taek Lee and more than 10 graduate students.
LEXINGTON, Ky. (July 7, 2015) — Ephraim McDowell Health last week announced that Ephraim McDowell Commonwealth Cancer Center (EMCCC) in Danville has joined the University of Kentucky Markey Cancer Center Affiliate Network. Kentucky faces some of the highest rates of cancer incidence and mortality in the nation, but EMCCC sees this relationship as stepping up the fight against cancer. The UK Markey Cancer Center is the state's first and only National Cancer Institute-designated cancer center.
Ephraim McDowell Health’s President and CEO Vicki Darnell said the announcement meant great things for their patients.
“The Ephraim McDowell Commonwealth Cancer Center affiliation with the UK Markey Cancer Center will allow us to provide new treatment options for our patients that are only available to National Cancer Institute-designated cancer centers," Darnell said. "We believe this is a big step in the continuing battle against cancer.”
"We are extremely excited and proud that our cancer treatment program is of the caliber that Markey Cancer Center would want to partner with us," said Dr. Tom Baeker, medical director of EMCCC Cancer Program. "This alliance means great things for our patients. It will enable us to offer access to the latest practices in diagnosis and treatment of cancers and blood disorders, including clinical trials – which means providing a higher level of cancer care."
The UK Markey Cancer Center Affiliate Network was created to provide high-quality cancer care closer to home for patients across the region, and to minimize the effects of cancer through prevention and education programs, exceptional clinical care, and access to research.
By becoming a UK Markey Cancer Center Affiliate, EMCCC is keeping with the organization’s mission to provide safe, compassionate, high quality, and cost-effective services to the communities served. The Ephraim McDowell Health system will now be able to offer their patients access to additional specialty and subspecialty physicians and care, including clinical trials and advanced technology, while allowing them to stay in Danville for most treatments.
The UK Markey Cancer Center Affiliate Network supports UK HealthCare's overall mission of ensuring no Kentuckian will have to leave the state to get access to top-of-the-line health care.
"Unfortunately, Kentucky is home to some of the worst rates of cancer in the country," said Dr. Tim Mullett, medical director of the UK Markey Cancer Center Affiliate Network. "By collaborating with our affiliate hospitals across the state, we have the potential to make a serious impact on cancer care here in the Commonwealth."
"UK HealthCare doesn't just serve Lexington and central Kentucky – our mission is to provide all Kentuckians with the best possible care right here in the state," said Dr. Michael Karpf, UK executive vice president for health affairs. "The Markey Cancer Center Affiliate Network allows us to collaborate with community hospitals to provide top-notch cancer care much closer to home — saving both travel expenses and time for the patients, in addition to keeping them close to their personal support system."
Markey is one of only 68 medical centers in the country to earn an NCI cancer center designation. Because of the designation, Markey patients have access to new drugs, treatment options and clinical trials offered only at NCI centers.
Video Produced by UK Public Relations & Marketing. To view captions for this video, push play and click on the CC icon in the bottom right hand corner of the screen. If using a mobile device, click on the "thought bubble" in the same area.
LEXINGTON, Ky. (June 25, 2015) — At one time, the plastic mesh head and neck mask Richard Powers wore during 33 rounds of radiation therapy was bound for the bottom of a lake. When asked what he’d do with the mask after six weeks of treatment, the University of Kentucky Markey Cancer Center patient told nurses he planned to hurl the mask into the water on a fishing trip.
But once he completed his treatment, Powers changed his mind about the fate of his mask. For the 75-year-old who’s battled three different types of cancer in his lifetime, an art therapy workshop at the UK Markey Cancer Center allowed him to reimagine the mask as a symbol of victory over his disease. Powers, a descendant of the Cherokee Nation, decided to transform the mask into a sculpture of a decorated Native American chief.
“I have Cherokee blood in me from my grandmother – they’re very strong people,” Powers said. “So I’m making him up as a warrior.”
During an art therapy workshop hosted at the UK Markey Cancer Center on May 29, Powers smeared handprints of bright red “war” paint across the cheeks of his Cherokee warrior. With help from his stepson Eddie Roberts, he assembled a headdress of feathers on the top of the chief head and attached a sheet of leather cut from an old purse across as a chest piece. A former member of the military, Powers hung an anchor symbolizing his service on one ear and a tiny fleur de lis, a token from a memorable trip, on the other ear.
“I’m going to take it home and put it in my living room somewhere hopefully or my hall entry way, and it will be a reminder and a conversation piece,” Powers said. “People will come in and say, ‘What is that?’ And I’ll be able to tell them that’s the mask I wore to cure my throat cancer.”
Throughout the summer, Fran Belvin, an art therapist with the UK Markey Cancer Center and UK Arts in HealthCare program, is hosting a series of mask-making workshops for head and neck cancer patients. The workshops include both a therapeutic and expressive component.
Belvin starts the day by leading the participants in a discussion of their experiences with radiation treatment, providing patients with the opportunity to share both positive and negative emotions tied to the treatment process and their mask. Then, the patients transition to an art studio setting where they use a varied array of art materials provided by Belvin, as well as personal items, to paint and embellish their masks.
Radiation treatment to the head and neck requires patients to wear a stiff plastic mesh mask to secure their positioning. Patients feel supressed and confined during the treatment process. Radiation for throat and head cancer causes patients to feel weak and tired, and can have long-term side-effects such as a hoarse voice and difficulty swallowing. Patients commonly fantasize about elaborate ways to rid themselves of the masks after treatment.
But given the opportunity to repurpose the mask, patients finished with radiation treatment are eager to let loose their imaginations and creativity. As a medium for art, Belvin said the large masks tend to inspire dramatic themes and extravagant interpretations of the self. The themes displayed through the masks range from humorous and gaudy to powerful and spiritual.
“It’s a way for the patient to transform the experience of having cancer and having radiation – which can be an uncomfortable and confining feeling – into something really positive and beautiful – or dramatic and exciting,” Belvin said.
Belvin is offering the workshops to any head or neck cancer patient from the Markey Cancer Center who has completed radiation treatment. If a patient did not keep their mask, one is provided. The workshops are scheduled one Friday per month throughout the summer. Participants may come just for the morning or the afternoon, or may stay all day. Patients also may come more than once to complete their sculptures and may bring a friend or family member to help them. Future workshops are scheduled to take place on June 26, July 24 and Aug. 21 from 10 a.m. to 3 p.m. To register or for more information, call Christina Jewell at (859) 323-4895.
MEDIA CONTACT: Elizabeth Adams, firstname.lastname@example.org; Allison Perry, email@example.com
LEXINGTON, Ky. (June 25, 2015) – Could a fatalistic attitude toward cervical cancer serve as a barrier to prevention of the disease? A recent study conducted by University of Kentucky researchers in the Rural Cancer Prevention Center suggests a link between fatalistic beliefs and completion of the human papillomavirus (HPV) vaccine series among a sample of young Appalachian Kentucky women.
The HPV vaccination series consists of three shots and helps prevent HPV infection and cervical cancer. Previous studies have shown that cost, lack of transportation, cultural views, and lack of knowledge about cervical cancer prevention as well as limited support from health care providers has prevented Appalachian women from getting or completing HPV vaccination in the past.
The concept of fatalism as it relates to health asserts that individuals perceive themselves to have limited control over what happens to their health and that health outcomes may be determined by fate. Previous research has found that some Appalachian women have reported fatalistic beliefs regarding their health, including the perception that being diagnosed with or preventing cancer is out of their control.
Published in The Journal of Rural Health, the study involved research nurses administering the first dose of the HPV vaccine series free of charge to Appalachian Kentucky women aged 18-26. The young women were then surveyed about their beliefs regarding cancer and followed for nine months after receiving the first dose to determine vaccination series completion; nearly 350 women participated in the study.
The study found that women who held fatalistic beliefs about their perceived lack of control over their health and cervical cancer had a significantly lower likelihood of completing the HPV vaccination series.
According to the Centers for Disease Control and Prevention, HPV is the most common sexually transmitted infection in the United States, affecting more than 79 million people. Nationally, Kentucky has some of the highest rates of HPV-related cancers; according to the Kentucky Cancer Registry, these elevated cancer rates are primarily attributable to cancer disparities observed in the 54-county Appalachian region of the state.
Almost all cervical cancers are caused by HPV, and several other cancers are linked to the virus as well, including head and neck, anal, penile, vulvar, and vaginal malignancies. Completing the vaccination series is the best way for young women (and men) to protect themselves against HPV infection and HPV-related cancers.
Personal beliefs like fatalism can serve as barrier to preventive health care measures such as HPV vaccination. Findings from the study indicate that fatalistic beliefs should be addressed in a culturally sensitive manner through education and tailored communication messaging. Such efforts may help increase HPV vaccination rates and decrease cervical cancer rates in Appalachian Kentucky.
"Results from this study may encourage health care providers to proactively assess and address young women’s personal health beliefs and develop a strategy for helping them complete the HPV vaccination series," Robin Vanderpool, associate professor in UK's Department of Health Behavior and deputy director of the Rural Cancer Prevention Center, said.
LEXINGTON, Ky. (June 19, 2015) — The University of Kentucky's Health Care Committee of the UK Board of Trustees were presented a strategic plan that will guide UK HealthCare through 2020. The committee met Thursday during their annual retreat.
Building upon the success of the past 10 years, the plan continues to emphasize caring for the most complex, critically ill patients in Kentucky and beyond.
Some of the statistics and figures presented that reflect UK HealthCare's growth include:
In approving the new strategic plan, UK HealthCare officials asked for a commitment from its leaders, stakeholders and partners to move forward and achieve its vision by giving latitude for collaborative models, committing to clinical excellence and providing an outstanding patient experience as well as service line integration. From its statewide partners, it was asked for participation in a statewide collaborative that fosters success against the challenges of the future.
"The 2020 Strategy is built on a foundation of patient-centered care and a patient-centered culture that includes growth in complex care as well as ambulatory care; strengthening partnership networks to reduce costs, and increase efficiency; and value-based care and payments which improve predictability of outcomes and cost while adopting evidence-based leading practices," said UK Vice President for Health Affairs Dr. Michael Karpf.
The plan includes developing a cultural change program in order to support the 2020 strategic vision. The program will identify key cultural strengths and opportunities. The goal will be to design a patient-centric experience that positions UK HealthCare to be Kentucky's destination provider for complex care and it will enable staff and leadership to be ambassadors of the patient-centered culture and UK HealthCare brand.
Also detailed in the Strategic Plan is growth in complex care and in ambulatory (outpatient care). As part of this goal, substantial service line growth is needed in the next five years. Additionally, ambulatory specialty care will also need to grow by improving access to UK HealthCare specialists and developing a patient-centered care model as well as partnering with community physicians.
As part of the service line growth, the focus will continue to be on treating the most complex patients and partnering with community providers to keep lower acuity patients in their home community.
Service line areas of primary focus for growth will be the Gill Heart Institute, Kentucky Children's Hospital, Markey Cancer Center, Kentucky Neuroscience Institute, High-Risk Obstetrics and Neonatal Intensive Care, Solid Organ Transplantation, Digestive Health, Musculoskeletal, and Trauma and Acute Care Surgery.
Clinical and support services that UK HealthCare will invest in to enable growth in these service lines includes excellence in quality and operational efficiency; redesigning the transfer management processes in order to create capacity and treat patients in the appropriate care setting and return them to our community partners; and develop a service line operating model to support and coordinate comprehensive, multidisciplinary care across the continuum and community.
These same strategies will be used to expand ambulatory specialty care.
To achieve this plan, a new service line operating model will be implemented to enable and enhance the organization's strategic initiatives. This new model will incorporate the transition from department and specialty driven care to multidisciplinary, multi-specialty care; episodic and high-acuity focused care to disease and cross continuum focused care; from provider centric to patient centric; from individual physician or specialty care to team care delivery involving multiple specialties; and UK HealthCare management of high-acuity care to collaboration with external partners to optimize site and level of care.
Integrated technology that standardizes data across the organization and enables population health management will be utilized.
Another overarching premise of the 2020 Strategic plan is the strengthening of partnership networks including acute care partnerships, post-acute care partnerships, primary care and community care. As part of future planning, UK will develop a primary care network to ensure a seamless experience across the care continuum and position the organization for value-based care and population health.
The third selected strategy in the plan is value-based care. In order to provide enhanced value for patients, UK HealthCare will develop a "best in class" quality management program.
This strategy includes improving the predictability of outcomes, cost of care, and adoption of evidence-based practices throughout the enterprise across all settings of care.
"To be successful, patient care in the future must be affordable, accessible, coordinated, efficient and high quality with a shift to improving health outcomes and rationalizing but not rationing care," said Karpf.
He added that although a significant amount of time and effort has been invested in developing this strategic plan, UK HealthCare’s strategic journey does not end here.
"We will continue with work in the weeks and months to come to set priorities, develop timelines, and track progress and results."
Media Contact: Kristi Lopez, 859-323-6363, Kristi.firstname.lastname@example.org
Read the latest annual report »